当前位置: X-MOL 学术Adv. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RNF219/α‐Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications
Advanced Science ( IF 14.3 ) Pub Date : 2020-12-31 , DOI: 10.1002/advs.202001961
Shuxia Zhang 1, 2 , Yingru Xu 1, 2 , Chan Xie 1, 2 , Liangliang Ren 1, 2 , Geyan Wu 3 , Meisongzhu Yang 2 , Xingui Wu 2 , Miaoling Tang 3 , Yameng Hu 2 , Ziwen Li 2 , Ruyuan Yu 2 , Xinyi Liao 2 , Shuang Mo 2 , Jueheng Wu 4 , Mengfeng Li 4 , Erwei Song 5 , Yanfei Qi 6 , Libing Song 3 , Jun Li 1, 2
Affiliation  

The incidence of bone metastases in hepatocellular carcinoma (HCC) has increased prominently over the past decade owing to the prolonged overall survival of HCC patients. However, the mechanisms underlying HCC bone‐metastasis remain largely unknown. In the current study, HCC‐secreted lectin galactoside‐binding soluble 3 (LGALS3) is found to be significantly upregulated and correlates with shorter bone‐metastasis‐free survival of HCC patients. Overexpression of LGALS3 enhances the metastatic capability of HCC cells to bone and induces skeletal‐related events by forming a bone pre‐metastatic niche via promoting osteoclast fusion and podosome formation. Mechanically, ubiquitin ligaseRNF219‐meidated α‐catenin degradation prompts YAP1/β‐catenin complex‐dependent epigenetic modifications of LGALS3 promoter, resulting in LGALS3 upregulation and metastatic bone diseases. Importantly, treatment with verteporfin, a clinical drug for macular degeneration, decreases LGALS3 expression and effectively inhibits skeletal complications of HCC. These findings unveil a plausible role for HCC‐secreted LGALS3 in pre‐metastatic niche and can suggest a promising strategy for clinical intervention in HCC bone‐metastasis.

中文翻译:

RNF219/α-Catenin/LGALS3 轴促进肝细胞癌骨转移及相关骨骼并发症

由于肝细胞癌(HCC)患者总生存期的延长,过去十年中肝细胞癌(HCC)骨转移的发生率显着增加。然而,HCC骨转移的机制仍然很大程度上未知。在目前的研究中,发现 HCC 分泌的凝集素半乳糖苷结合可溶性 3 (LGALS3) 显着上调,并且与 HCC 患者较短的无骨转移生存期相关。LGALS3的过度表达增强了HCC细胞的骨转移能力,并通过促进破骨细胞融合和足体形成形成骨转移前生态位来诱导骨骼相关事件。从机械角度来看,泛素连接酶RNF219介导的α-连环蛋白降解会促使LGALS3启动子发生YAP1/ β-连环蛋白复合物依赖性表观遗传修饰,导致LGALS3上调和转移性骨疾病。重要的是,使用治疗黄斑变性的临床药物维替泊芬治疗,可以降低LGALS3的表达,并有效抑制HCC的骨骼并发症。这些发现揭示了 HCC 分泌的 LGALS3 在转移前微环境中的合理作用,并为 HCC 骨转移的临床干预提供了一种有前景的策略。
更新日期:2021-02-17
down
wechat
bug